Comparing SG&A Expenses: Pfizer Inc. vs CRISPR Therapeutics AG Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Pfizer Inc. and CRISPR Therapeutics AG from 2014 to 2023.

Pfizer Inc.: A Steady Giant

Pfizer, a stalwart in the pharmaceutical sector, consistently reported SG&A expenses around $14 billion annually. Despite a dip in 2020, likely due to pandemic-related adjustments, Pfizer's expenses rebounded, showcasing its robust operational framework.

CRISPR Therapeutics AG: A Rising Innovator

In contrast, CRISPR Therapeutics AG, a pioneer in gene-editing technology, exhibited a dynamic growth trajectory. Starting with modest expenses in 2014, the company saw a staggering increase of over 1,800% by 2021, reflecting its aggressive expansion and innovation strategies.

This comparative analysis highlights the diverse financial strategies of established giants and emerging innovators in the pharmaceutical industry.